T

Į,

02-11-02

PTO/SB/05 (03-01) Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

Please type a plus sign (+) inside this box

29.US4.DIV Attorney Docket No. Bernard BIHAIN, et al. First Inventor Lipoprotein-Regulating Medicaments

EL 821903127 US Express Mail Label No. (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: **Box Patent Application** Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or 1. (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) Specification [Total Pages (preferred arrangement set forth below) Computer Readable Form (CRF) x - Descriptive title of the invention Specification Sequence Listing on: - Cross Reference to Related Applications CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, ii. x paper or a computer program listing appendix c. | x | Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) **ACCOMPANYING APPLICATION PARTS** - Detailed Description 9. Assignment Papers (cover sheet & document(s)) - Claim(s) Power of 37 CFR 3.73(b) Statement 10. - Abstract of the Disclosure Attorney (when there is an assignee) English Translation Document (if applicable) 4. × Drawing(s) (35 U.S.C. 113) [Total Sheets Copies of IDS Information Disclosure [Total Pages Citations 5. Oath or Declaration Statement (IDS)/PTO-1449 Preliminary Amendment Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) a. Return Receipt Postcard (MPEP 503) b. (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** Signed statement attached deleting inventor(s) Nonpublication Request under 35 U.S.C. 122 named in the prior application, see 37 CFR (b)(2)(B)(i). Applicant must attach form PTO/SB/35 1.63(d)(2) and 1.33(b). or its equivalent. 6. × Application Data Sheet. See 37 CFR 1.76 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: 485,316 Continuation × Divisional Continuation-in-part (CIP) of prior application No.:_ Group Art Unit. Prior application information: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS 000027206 x Correspondence address below Customer Number or Bar Code Labe (Insert Customer No. or Attach bar code label here) John Lucas, Ph.D., J.D. Name GENSET CORPORATION 10665 Sorrento Valley Road <u>Address</u> 92121-1609 State Zip Code San Diego City 858/597-2600 858/597-2601 Fax U.S.A. Country Telephone Registration No. (Attorney/Agent) 43,373 John Lucas, Ph.D., J.D. Name (Print/Type) Signature

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

The season of th

22

l	(\$)	1,076.00	0
l	(\$)	1,0	<i>11</i> 0.0


Complete if Known					
Application Number					
Filing Date	February 5, 2002				
First Named Inventor	Bernard BIHAIN, ET AL.				
Examiner Name	J. Taylor Cleveland				
Group Art Unit	1655				
Attorney Docket No.	29.US4.DIV				

METHOD OF PAYMENT						FEE CALCULATION (continued)						
The Commissioner is hereby authorized to charge						3. ADDITIONAL FEES						
٠.	لثا Depos		ated fees	and credit any overpaym	ents to:		Large		Smal			
	Accou	ınt j		50-1181	1	Fee	Entit	y Fee	Entit Fee	y Fee Description	Fee Paid	
	Numb	=				Code		Code		ree Description	1001414	
	Accou	ınt		Genset Corporation		105	130	205	65	Surcharge - late filing fee or oath		
		Charge	Any Addition	onal Fee Required		127	50	227	25	Surcharge - late provisional filing fee or cover sheet		
				mall entity status.		139	130	139	130	Non-English specification		
			CFR 1.27			147	2,520	147	2,520	For filing a request for ex parte reexamination		
2.		Payr Check	ment End	redit card Money	Other	112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
	ٔ ت	0,100.		CALCULATION	<u> </u>	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
4	DAG	10 E	ILING F			115	110	215	55	Extension for reply within first month		
1.			y Small E			116	400	216	200	Extension for reply within second month		
	Fee	Fee	Fee F	ee Fee Description	Fee Paid	117	920	217	460	Extension for reply within third month		
	Code	• • •	Code (201 37	•		118	1,440	218	720	Extension for reply within fourth month		
	101 106.		201 37		740	128	1,960	228	980	Extension for reply within fifth month		
	107		200 10			119	320	219	160	Notice of Appeal		
	108		208 37	-		120	320	220	160	Filing a brief in support of an appeal		
	114		214 8	•		121	280	221	140	Request for oral hearing		
	117	. 100	217 0			138	1,510	138	1,510	Petition to institute a public use proceeding		
SUBTOTAL (1) (\$) 740.00					140	110	240	55	Petition to revive - unavoidable			
2.	EXT	RA (CLAIM I			141	1,280	241	640	Petition to revive - unintentional		
					e from elow Fee Paid	142	1,280	242	640	Utility issue fee (or reissue)	<u> </u>	
	al Clair		14	-20** = 0 X	18 = 0	143	460	243	230	Design issue fee		
	epende ims	ent	7	- 3** = 4 X	84 = 336	144	620	244	310	Plant issue fee		
	ıltiple D	Depen	dent		=0	122	130	122	130	Petitions to the Commissioner		
						123	50	123	50	Processing fee under 37 CFR 1.17(q)		
			Small Er			126	180	126	180	Submission of Information Disclosure Stmt		
	Code		Fee Fe Code (\$) 203 9			581	40	581	40	Recording each patent assignment per property (times number of properties)		
			202 42	Independent claims	in excess of 3	146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))		
	104 2	80.	204 140	Multiple dependent		149	740	249	370	For each additional invention to be		
	109	84.	209 42	** Reissue indepen- over original pate						examined (37 CFR § 1.129(b))		
	110	18	210 9	** Reissue claims II		179 169	740	279	370	Request for Continued Examination (RCE)		
				and over original	over original patent		900	169	900	Request for expedited examination of a design application		
SUBTOTAL (2) (\$) 336.00						Other	fee (s	pecify	·)			
	**or nui	mber		paid, if greater; For Rei	ssues, see above	*Red	uced b	y Bas	ıc Filing	Fee Paid SUBTOTAL (3)	0.00	

SUBMITTED BY	Express Mail Label No. EL 821903127	Complete (if applicable)				
Name (Print/Type)	John Lugas, Ph.D., J.D.	Registration No. (Attorney/Agent)	43,373	Telephone	(858) 597-2600	
Signature	John From	n		Date	2/5/02	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



E

Direct Dial: (858) 597-2610 E-Mail: john.lucas@genxy.com Τ

February 5, 2002

Express Mail Label No. EL 821903127 US

Assistant Commissioner for Patents Box: Patent Application Washington, D.C. 20231

RE:

Ε

U.S. Divisional Patent Application

For: LIPOPROTEIN-REGULATING MEDICAMENTS

Inventor(s): Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin

Our Ref.: 29.US4.DIV

Dear Sir:

Enclosed please find the above-identified utility patent application for filing with the United States Patent and Trademark Office. This application is a divisional application of U.S. Serial No. 09/485,316, filed February 4, 2000, which claimed priority under 35 U.S.C. §371 to PCT/ IB98/01256, filed August 6, 1998, which claimed priority on French Patent Application No. 97 10088, filed August 6, 1997, and to Application No. 98 05032, filed April 22, 1998. The following documents are transmitted herewith:

	Qι	iantity
Specification and Claims	52	pages
Figures 1-7B	7	sheets
Application Data Sheet	4	pages
Preliminary Amendment	6	pages
Utility Patent Application Transmittal, Fee Transmittal for FY 2002, Patent	3	sheets
Application Fee Determination Record		
Our check #3623 in the amount of \$1,076.00 for the filing fee		
Paper copy of Sequence Listing	20	pages
Sequence Listing Verification Statement under 1.821	1	page
Photocopy of Declaration and Power of Attorney as filed in S/N 09/485,316	2	pages
Revocation and Power of Attorney; Statement under 37 CFR 3.73(b)	2	pages
Return Receipt Postcard		
	Figures 1-7B Application Data Sheet Preliminary Amendment Utility Patent Application Transmittal, Fee Transmittal for FY 2002, Patent Application Fee Determination Record Our check #3623 in the amount of \$1,076.00 for the filing fee Paper copy of Sequence Listing Sequence Listing Verification Statement under 1.821 Photocopy of Declaration and Power of Attorney as filed in S/N 09/485,316 Revocation and Power of Attorney; Statement under 37 CFR 3.73(b)	Specification and Claims Figures 1-7B Application Data Sheet Preliminary Amendment Utility Patent Application Transmittal, Fee Transmittal for FY 2002, Patent Application Fee Determination Record Our check #3623 in the amount of \$1,076.00 for the filing fee Paper copy of Sequence Listing Sequence Listing Verification Statement under 1.821 Photocopy of Declaration and Power of Attorney as filed in S/N 09/485,316 Revocation and Power of Attorney; Statement under 37 CFR 3.73(b) 2 2 2 2 2 2 2 2 2 2 2 2 2

The Commissioner is hereby authorized to charge any additional fees, or credit any overpayment in the processing of these documents to our Deposit Account No. 50-1181.

Very truly yours,

GENSET CORPORATION

John Lucas, Ph.D., J.D

Reg. No. 43,373

JL/AS/cmm Enclosures

cc: Helene Sarraseca (w/encls.)

Certificate of Mailing under 37 CFR 1.10

Express Mail Label No.: <u>EL 821903127 US</u>
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the Date of Deposit shown above, postage prepaid and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

racents and Trademarks, Washington, D.C. 20231.

AARON J. SCALIA
Typed or Printed Name of Person Striping Certificate

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Divi	sion	al Patent Application of:		
Inventor(s)	:	Bernard Bihain, Lydie Bougueleret,) Frances Yen-Potin)	Art Unit	1655
Serial No.	:)))		J. Taylor Cleveland
Filed	:	February 5, 2002		
Parent Appl	icati	on:)		
Seri	al N	o. : 09/485,316)	· 	
Filing	g Da	re: February 4, 2000)))	
Title	:	LIPOPROTEIN-REGULATING) MEDICAMENTS)) }	

SUBMISSION OF SEQUENCE LISTING AND STATEMENT UNDER 1.821

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The paper copy of the Sequence Listing in this application is identical to the computer readable copy of the Sequence Listing filed in application Serial Number 09/485,316, filed February 4, 2000.

In accordance with 37 CFR 1.821(e), please use the computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper copy of the Sequence Listing was included in the originally-filed specification of the instant application. The undersigned hereby certifies that the paper and computer readable copies contain the same information.

The Commissioner is hereby authorized to credit any overpayment or charge any additional fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to our Deposit Account No. 50-1181.

Respectfully submitted,

GENSET CORPORATION

Date: $2/5/0\nu$, 2002

By:

John Lucas, Ph.D., J.D.

Registration No. 43,373

10665 Sorrento Valley Road San Diego, CA 92121-1609

Telephone: (858) 597-2600 Facsimile: (858) 597-2601

e-mail: john.lucas@genxy.com

Certificate of Mailing under 37 CFR 1.10

Express Mail Label No.: EL 821903127 US

Date of Deposit:

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the Date of Deposit shown above, postage prepaid and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

SCALIA

Signature

AARON J.

Typed or Printed Name of Person Signing Certificate